Selecta Biosciences, Inc. (SELB): Price and Financial Metrics
GET POWR RATINGS... FREE!
SELB POWR Grades
- Sentiment is the dimension where SELB ranks best; there it ranks ahead of 85.05% of US stocks.
- SELB's strongest trending metric is Quality; it's been moving down over the last 179 days.
- SELB ranks lowest in Momentum; there it ranks in the 12th percentile.
SELB Stock Summary
- Of note is the ratio of Selecta Biosciences Inc's sales and general administrative expense to its total operating expenses; merely 9.92% of US stocks have a lower such ratio.
- SELB's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 0.73% of US stocks.
- As for revenue growth, note that SELB's revenue has grown 412.61% over the past 12 months; that beats the revenue growth of 98.02% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Selecta Biosciences Inc, a group of peers worth examining would be ATHX, MGNX, CLLS, IMGN, and LPTX.
- SELB's SEC filings can be seen here. And to visit Selecta Biosciences Inc's official web site, go to selectabio.com.
SELB Valuation Summary
- In comparison to the median Healthcare stock, SELB's EV/EBIT ratio is 132.76% lower, now standing at -9.6.
- Over the past 63 months, SELB's EV/EBIT ratio has gone down 0.7.
- SELB's price/earnings ratio has moved down 2.2 over the prior 63 months.
Below are key valuation metrics over time for SELB.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SELB | 2021-08-31 | 10.6 | -118.3 | -11.0 | -9.6 |
| SELB | 2021-08-30 | 10.5 | -117.5 | -11.0 | -9.5 |
| SELB | 2021-08-27 | 9.8 | -109.6 | -10.2 | -8.7 |
| SELB | 2021-08-26 | 9.7 | -109.0 | -10.2 | -8.7 |
| SELB | 2021-08-25 | 9.9 | -110.9 | -10.4 | -8.9 |
| SELB | 2021-08-24 | 9.8 | -110.1 | -10.3 | -8.8 |
SELB's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SELB has a Quality Grade of B, ranking ahead of 76.01% of graded US stocks.
- SELB's asset turnover comes in at 0.269 -- ranking 167th of 682 Pharmaceutical Products stocks.
- QGEN, ALPN, and TXMD are the stocks whose asset turnover ratios are most correlated with SELB.
The table below shows SELB's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.269 | 1 | 7.960 |
| 2021-03-31 | 0.185 | 1 | 57.591 |
| 2020-12-31 | 0.130 | 1 | -35.918 |
| 2020-09-30 | 0.102 | 1 | -12.988 |
| 2020-06-30 | 0.088 | 1 | -11.186 |
| 2020-03-31 | 0.097 | 1 | -19.349 |
SELB Price Target
For more insight on analysts targets of SELB, see our SELB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $8.67 | Average Broker Recommendation | 1.29 (Strong Buy) |
SELB Stock Price Chart Interactive Chart >
SELB Price/Volume Stats
| Current price | $0.71 | 52-week high | $5.28 |
| Prev. close | $0.69 | 52-week low | $0.65 |
| Day low | $0.67 | Volume | 923,600 |
| Day high | $0.72 | Avg. volume | 1,160,520 |
| 50-day MA | $1.03 | Dividend yield | N/A |
| 200-day MA | $2.73 | Market Cap | 107.22M |
Selecta Biosciences, Inc. (SELB) Company Bio
Selecta Biosciences, Inc., a clinical-stage biotechnology company, develops targeted therapies that use immunomodulators encapsulated in nanoparticles to induce antigen-specific immune responses to prevent and treat disease. The company was founded in 2007 and is based in Watertown, Massachusetts.
Latest SELB News From Around the Web
Below are the latest news stories about Selecta Biosciences Inc that investors may wish to consider to help them evaluate SELB as an investment opportunity.
Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and Selecta Biosciences (SELB)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Avadel Pharmaceuticals (AVDL – Research Report) and Selecta Biosciences (SELB – Research Report) with bullish sentiments. Avadel Pharmaceuticals (AVDL) Needham analyst Ami Fadia maintained a Buy rating on Avadel Pharmaceuticals today and set a price target of $15.00. The company's shares closed last Monday at $6.92, close to its 52-week low of $6.29. According to TipRanks. |
Horizon (HZNP) Submits sBLA for Krystexxa Label ExpansionHorizon (HZNP) files a supplemental biologics license application to the FDA for Krystexxa plus methotrexate to treat people living with uncontrolled gout. |
Selecta taps Ginkgo for deal worth up to $1.1BSelecta Biosciences Inc. has chosen Ginkgo Bioworks Holdings Inc. to develop new viral capsids for gene therapies. |
Selecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-Generation Gene Therapy CapsidsSelecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to develop safer and more effective next-generation gene therapy viral capsids. This partnership leverages the unique platforms of both companies as they seek to develop next-g |
Selecta Biosciences (SELB) Investor Presentation - SlideshowNo summary available. |
SELB Price Returns
| 1-mo | -20.47% |
| 3-mo | -61.83% |
| 6-mo | -75.52% |
| 1-year | -80.11% |
| 3-year | -69.79% |
| 5-year | -94.95% |
| YTD | -78.22% |
| 2021 | 7.59% |
| 2020 | 27.31% |
| 2019 | -10.53% |
| 2018 | -72.88% |
| 2017 | -42.80% |
Loading social stream, please wait...